onzigolide (TBR-760) / Ipsen, Tiburio - LARVOL DELTA

Dandelion root extracts abolish MAPK pathways to ameliorate experimental mouse ulcerative colitis. (PubMed, Adv Clin Exp Med) - "The DRE-H is capable of relieving DSS-induced UC, and its mechanism links to the MAPK pathways."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • MAPK8 • RELA

Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. (PubMed, Pituitary) - "TBR-065 has significantly improved efficacy in suppressing GH secretion as compared to current available therapies and may represent a new promising option for the treatment of acromegaly."

Journal • Acromegaly • Endocrine Disorders • Oncology

Clinical trial to assess the safety, tolerability and efficacy of TBR-760 in patients with Non-Functioning Pituitary Adenomas (clinicaltrialsregister.eu) - P2; N=150; Ongoing; Sponsor: Tiburio Therapeutics, Inc.

Clinical • New P2 trial • Brain Cancer • Oncology • Solid Tumor

TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Non-Functioning Pituitary Adenomas in Mice. (PubMed, Endocrinology) - "Further, significant tumor shrinkage was observed in 20% of the mice treated with TBR-760. These results support the development of TBR-760 as a therapy for patients with NFPA."

Journal • Preclinical • Oncology

[VIRTUAL] TBR-760, a Chimeric Somatostatin-Dopamine Compound, Arrests Aggressive Non-Functioning Pituitary Adenoma Growth In Vivo (ENDO-I 2020) - "Further, despite the highly aggressive nature of the POMC-KO tumors, significant tumor shrinkage was observed in 20% of the mice treated with TBR-760. These results support the development of TBR-760 as a medical therapy to prevent or arrest the growth of NFPAs and, potentially, to induce NFPA shrinkage."

Preclinical • Oncology • MRI

".@TiburioT’s TBR-760 arrests aggressive non-functioning #pituitary #adenoma growth in mouse #model, #ENDO2020 hears 20% of mice receiving #dopamine #somatostatin chimeric compound saw #tumors shrink https://t.co/k2MK3KMYQP #oncology #cancers @IpsenUS" (@DDNewsOnline)

Preclinical • Oncology

Tiburio announces publication of preclinical TBR-760 data in non-functioning pituitary adenoma in Journal of the Endocrine Society (GlobeNewswire, Tiburio Therapeutics) - "Key data from the study included: TBR-760 treatment, initiated when the mice had an established tumor, completely arrested tumor growth throughout the 8 week treatment period; Final average tumor volume in TBR-760-treated mice was 8.5±1.3mm3 vs. 54.61±10.6mm3 in vehicle-treated mice (p<0.05); Treatment with equimolar or 10x-higher doses of the individual somatostatin or dopamine, alone or in combination, had little to no effect on tumor growth, except in the lower dose dopamine group where a modest suppression of tumor growth was observed."

Preclinical

TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas (clinicaltrials.gov) - P2; N=150; Not yet recruiting; Sponsor: Tiburio Therapeutics

Clinical • New P2 trial